본문 바로가기
KERD
논문KCI 등재

The resurrection of RIP kinase 1 as an early cell death checkpoint regulator—a potential target for therapy in the necroptosis era

허강민|Shen Han-Ming|Ju Eunjin|Park Kyeong Ah
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2022.12|Experimental and Molecular Medicine|제54권 |pp. 1-11|DOI 10.1038/s12276-022-00847-4

1

조회

0

다운로드

1

인용

0

참고문헌

주제분류생화학

초록

Receptor-interacting serine threonine protein kinase 1 (RIPK1) has emerged as a central molecular switch in controlling the balance between cell survival and cell death. The pro-survival role of RIPK1 in maintaining cell survival is achieved via its ability to induce NF-κB-dependent expression of anti-apoptotic genes. However, recent advances have identified the pro-death function of RIPK1: posttranslational modifications of RIPK1 in the tumor necrosis factor receptor 1 (TNFR1)-associated complex-I, in the cytosolic complex-IIb or in necrosomes regulate the cytotoxic potential of RIPK1, forming an early cell death checkpoint. Since the kinase activity of RIPK1 is indispensable in RIPK3- and MLKL-mediated necroptosis induction, while it is dispensable in apoptosis, a better understanding of this early cell death checkpoint via RIPK1 might lead to new insights into the molecular mechanisms controlling both apoptotic and necroptotic modes of cell death and help develop novel therapeutic approaches for cancer. Here, we present an emerging view of the regulatory mechanisms for RIPK1 activity, especially with respect to the early cell death checkpoint. We also discuss the impact of dysregulated RIPK1 activity in pathophysiological settings and highlight its therapeutic potential in treating human diseases.

Abstract

Receptor-interacting serine threonine protein kinase 1 (RIPK1) has emerged as a central molecular switch in controlling the balance between cell survival and cell death. The pro-survival role of RIPK1 in maintaining cell survival is achieved via its ability to induce NF-κB-dependent expression of anti-apoptotic genes. However, recent advances have identified the pro-death function of RIPK1: posttranslational modifications of RIPK1 in the tumor necrosis factor receptor 1 (TNFR1)-associated complex-I, in the cytosolic complex-IIb or in necrosomes regulate the cytotoxic potential of RIPK1, forming an early cell death checkpoint. Since the kinase activity of RIPK1 is indispensable in RIPK3- and MLKL-mediated necroptosis induction, while it is dispensable in apoptosis, a better understanding of this early cell death checkpoint via RIPK1 might lead to new insights into the molecular mechanisms controlling both apoptotic and necroptotic modes of cell death and help develop novel therapeutic approaches for cancer. Here, we present an emerging view of the regulatory mechanisms for RIPK1 activity, especially with respect to the early cell death checkpoint. We also discuss the impact of dysregulated RIPK1 activity in pathophysiological settings and highlight its therapeutic potential in treating human diseases.

참고문헌 (182)

  1. Fink, S. L., "Apoptosis, pyroptosis, and necrosis : mechanistic description of dead and dying eukaryotic cells", Infect. Immun, 73, pp.1907~1916 (2005)
  2. Kroemer, G., "The mitochondrial death", life regulator in apoptosis and necrosis, 1998, pp.60, 619~642
  3. Ellis, H. M., "Genetic control of programmed cell death in the nematode C. elegans", Cell, 44, pp.817~829 (1986)
  4. Hengartner, M. O., "Programmed cell death in the nematode C. elegans", Recent Prog. Horm. Res, 54, pp.213~222 (1999)
  5. Earnshaw, W. C., "Mammalian caspases : structure, activation, substrates, and functions during apoptosis", Annu. Rev. Biochem, 68, pp.383~424 (1999)
  6. Dixit, V. M., "Role of ICE-proteases in apoptosis", Adv. Exp. Med. Biol, 406, pp.113~117 (1996)
  7. Kawahara, A., "Caspaseindependent cell killing by Fas-associated protein with death domain", J. Cell Biol, 143, pp.1353~1360 (1998)
  8. Vanden, B. T., "More than one way to die: methods to determine TNFinduced apoptosis and necrosis", Methods Mol. Med, 98, pp.101~126 (2004)
  9. Lin, Y., "Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation", J. Biol. Chem, 279, pp.10822~10828 (2004)
  10. Vandenabeele, P., "Molecular mechanisms of necroptosis: an ordered cellular explosion", Nat. Rev. Mol. Cell Biol, 11, pp.700~714 (2010)
  11. Cho, Y. S., "Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation", Cell, 137, pp.1112~1123 (2009)
  12. Chen, X., "Mosaic composition of RIP1–RIP3 signalling hub and its role in regulating cell death", Nat. Cell Biol, 24, pp.471~482 (2022)
  13. Stanger, B. Z., "RIP : a novel protein containing a death domain that interacts with Fas", APO-1(CD95)in yeast and causes cell death, 1995, pp.81, 513~523
  14. Hsu, H., "The TNF receptor 1–associated protein TRADD signals cell death and NF-κB activation", Cell, 81, pp.495~504 (1995)
  15. Sun, X., "RIP3, a novel apoptosis-inducing kinase", J. Biol. Chem, 274, pp.16871~16875 (1999)
  16. Newton, K., "RIPK1 and RIPK3 : critical regulators of inflammation and cell death", Trends Cell Biol, 25, pp.347~353 (2015)
  17. O’Donnell, M. A., "NF-κB and ubiquitination : partners in disarming RIPK1-mediated cell death", Immunol. Res, 54, pp.214~226 (2012)
  18. 원민호, "Post-translational control of NF-jB signaling by ubiquitination", Archives of Pharmacal Research, 39(8), pp.1075~1084 (2016), 대한약학회
  19. Declercq, W., "RIP kinases at the crossroads of cell death and survival", Cell, 138, pp.229~232 (2009)
  20. Hinz, M., "The IκB kinase complex in NF-κB regulation and beyond", EMBO Rep, 15, pp.46~61 (2014)
  21. Chen, Z. J., "Ubiquitin signalling in the NF-kappaB pathway", Nat. Cell Biol, 7, pp.758~765 (2005)
  22. Tsuchiya, Y., "FLIP the switch : regulation of apoptosis and necroptosis by cFLIP", Int. J. Mol. Sci, 16, pp.30321~30341 (2015)
  23. Hughes, M. A., "Co-operative and hierarchical binding of c-FLIP and caspase-8 : a unified model defines how c-FLIP isoforms differentially control cell fate", Mol. Cell, 61, pp.834~849 (2016)
  24. Karin, M., "NF-kappaB at the crossroads of life and death", Nat. Immunol, 3, pp.221~227 (2002)
  25. Annibaldi, A., "Checkpoints in TNF-induced cell death : implications in inflammation and cancer", Trends Mol. Med, 24, pp.49~65 (2018)
  26. Ting, A. T., "More to life than NF-κB in TNFR1 signaling", Trends Immunol, 37, pp.535~545 (2016)
  27. Kidong Kang, "Post-translational modification of the death receptor complex as a potential therapeutic target in cancer", Archives of Pharmacal Research, 42(1), pp.76~87 (2019), 대한약학회[DOI]
  28. Newton, K., "Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis", Science, 343, pp.1357~1360 (2014)
  29. Newton, K., "Multitasking kinase RIPK1 regulates cell death and inflammation", Cold Spring Harb. Perspect. Biol, 12, pp.a036368~ (2020)
  30. Xu, Q., "Switching from TNF-induced inflammation to death signaling", Mol. Cell. Oncol, 5, pp.e1392402~ (2017)
  31. Chen, G., "TNF-R1 signaling : a beautiful pathway", Science, 296, pp.1634~1635 (2002)
  32. Dynek, J. N., "c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling", EMBO J, 29, pp.4198~4209 (2010)
  33. Peltzer, N., "Holding RIPK1 on the ubiquitin leash in TNFR1 signaling", Trends Cell Biol, 26, pp.445~461 (2016)
  34. Dondelinger, Y., "MK2 phosphorylation of RIPK1 regulates TNF-mediated cell death", Nat. Cell Biol, 19, pp.1237~1247 (2017)
  35. Haas, T. L., "Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction", Mol. Cell, 36, pp.831~844 (2009)
  36. Hsu, H., "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways", Cell, 84, pp.299~308 (1996)
  37. Zhang, L., "The RING domain of TRAF2 plays an essential role in the inhibition of TNFα-induced cell death but not in the activation of NF-κB", J. Mol. Biol, 396, pp.528~539 (2010)
  38. Yin, Q., "Structural basis for the lack of E2interaction in the RING domain of TRAF2", Biochemistry, 48, pp.10558~10567 (2009)
  39. Vince, J. E., "TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor(tnf)to efficiently activate nf-kappab and to prevent tnf-induced apoptosis", J. Biol. Chem, 284, pp.35906~35915 (2009)
  40. Yeh, W. C., "Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice", Immunity, 7, pp.715~725 (1997)
  41. Tada, K., "Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death", J. Biol. Chem, 276, pp.36530~36534 (2001)
  42. Pobezinskaya, Y. L., "The function of TRADD in signaling through tumor necrosis factor receptor 1 and TRIF-dependent Toll-like receptors", Nat. Immunol, 9, pp.1047~1054 (2008)
  43. Zhang, L., "TRAF2 suppresses basal IKK activity in resting cells and TNFα can activate IKK in TRAF2 and TRAF5 double knockout cells", J. Mol. Biol, 389, pp.495~510 (2009)
  44. Mahoney, D. J., "Both cIAP1 and cIAP2 regulate TNFα-mediated NF-κB activation", Proc. Natl Acad. Sci. USA, 105, pp.11778~11783 (2008)
  45. Bertrand, M. J., "cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination", Mol. Cell, 30, pp.689~700 (2008)
  46. Varfolomeev, E., "c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha(TNFα)-induced NF-κB activation", J. Biol. Chem, 283, pp.24295~24299 (2008)
  47. Zheng, C., "Crystal structures of the TRAF2 : cIAP2 and the TRAF1 : TRAF2 : cIAP2 complexes : affinity, specificity, and regulation", Mol. Cell, 38, pp.101~113 (2010)
  48. Rothe, M., "The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins", Cell, 83, pp.1243~1252 (1995)
  49. Moulin, M., "IAPs limit activation of RIP kinases by TNF receptor 1 during development", EMBO J, 31, pp.1679~1691 (2012)
  50. Emmerich, C. H., "The linear ubiquitin chain assembly complex forms part of the TNF-R1 signalling complex and is required for effective TNF-induced gene induction and prevents TNF-induced apoptosis", Adv. Exp. Med. Biol, 691, pp.115~126 (2011)
  51. Gerlach, B., "Linear ubiquitination prevents inflammation and regulates immune signalling", Nature, 471, pp.591~596 (2011)
  52. de Almagro, M. C., "Cellular IAP proteins and LUBAC differentially regulate necrosome-associated RIP1 ubiquitination", Cell Death Dis, 6, pp.e1800~ (2015)
  53. Rieser, E., "Linear ubiquitination: a newly discovered regulator of cell signalling", Trends Biochem. Sci, 38, pp.94~102 (2013)
  54. Tokunaga, F., "LUBAC, a novel ubiquitin ligase for linear ubiquitination, is crucial for inflammation and immune responses", Microbes Infect, 14, pp.563~572 (2012)
  55. Peltzer, N., "HOIP deficiency causes embryonic lethality by aberrant TNFR1-mediated endothelial cell death", Cell Rep, 9, pp.153~165 (2014)
  56. Ikeda, F., "SHARPIN forms a linear ubiquitin ligase complex regulating NFkappaB activity and apoptosis", Nature, 471, pp.637~341 (2011)
  57. Tokunaga, F., "SHARPIN is a component of the NF-kappaBactivating linear ubiquitin chain assembly complex", Nature, 471, pp.633~636 (2011)
  58. Emmerich, C. H., "Activation of the canonical IKK complex by K63", M1-linked hybrid ubiquitin chains, 2013, pp.110, 15247~15252
  59. Fiil, B. K., "OTULIN restricts Met1-linked ubiquitination to control innate immune signaling", Mol. Cell, 50, pp.818~830 (2013)
  60. Peltzer, N., "LUBAC is essential for embryogenesis by preventing cell death and enabling haematopoiesis", Nature, 557, pp.112~127 (2018)
  61. Nanda, S. K., "Polyubiquitin binding to ABIN1 is required to prevent autoimmunity", J. Exp. Med, 208, pp.1215~1228 (2011)
  62. Dziedzic, S. A., "ABIN-1 regulates RIPK1 activation by linking Met1 ubiquitylation with Lys63 deubiquitylation in TNF-RSC", Nat. Cell Biol, 20, pp.58~68 (2018)
  63. Cai, J., "ABIN-1 is a key regulator in RIPK1-dependent apoptosis(RDA)and necroptosis, and ABIN-1 deficiency potentiates necroptosis-based cancer therapy in colorectal cancer", Cell Death Dis, 12, pp.140~ (2021)
  64. Feltham, R., "Mind bomb regulates cell death during TNF signaling by suppressing RIPK1’s cytotoxic potential", Cell Rep, 23, pp.470~484 (2018)
  65. Schneider-Brachert, W., "Compartmentalization of TNF receptor 1 signaling : internalized TNF receptosomes as death signaling vesicles", Immunity, 21, pp.415~428 (2004)
  66. Mosselmans, R., "Endocytic pathway of recombinant murine tumor necrosis factor in L-929 cells", J. Immunol, 141, pp.3096~3100 (1988)
  67. Schutze, S., "Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signaling", J. Biol. Chem, 274, pp.10203~10212 (1999)
  68. Tchikov, V., "Subcellular compartmentalization of TNF receptor-1 and CD95 signaling pathways", Eur. J. Cell Biol, 90, pp.467~475 (2010)
  69. Polo, S., "A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins", Nature, 416, pp.451~455 (2002)
  70. Hofmann, K., "A ubiquitin-interacting motif conserved in components of the proteasomal and lysosomal protein degradation systems", Trends Biochem. Sci, 26, pp.347~350 (2001)
  71. Won, M., "ANKRD13a controls early cell-death checkpoint by interacting with RIP1 independent of NF-kappaB", Cell Death Differ, 29, pp.1152~1163 (2021)
  72. Song, K., "Epsins 1 and 2 promote NEMO linear ubiquitination via LUBAC to drive breast cancer development", J. Clin. Invest, 131, pp.e129374~ (2021)
  73. Coornaert, B., "A20 : central gatekeeper in inflammation and immunity", J. Biol. Chem, 284, pp.8217~8221 (2009)
  74. Wertz, I. E., "De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling", Nature, 430, pp.694~699 (2004)
  75. Newton, K., "Ubiquitin chain editing revealed by polyubiquitin linkagespecific antibodies", Cell, 134, pp.668~678 (2008)
  76. Lee, E. G., "Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice", Science, 289, pp.2350~2354 (2000)
  77. Bellail, A. C., "A20 ubiquitin ligasemediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAILinduced apoptosis in glioblastoma", Cancer Disco, 2, pp.140~155 (2012)
  78. Daniel, S., "A20 protects endothelial cells from TNF-, Fas-, and NK-mediated cell death by inhibiting caspase 8 activation", Blood, 104, pp.2376~2384 (2004)
  79. Lu, T. T., "Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme", Immunity, 38, pp.896~905 (2013)
  80. Verhelst, K., "A20 inhibits LUBAC-mediated NF-κB activation by binding linear polyubiquitin chains via its zinc finger 7", EMBO J, 31, pp.3845~3855 (2012)
  81. Draber, P., "LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes", Cell Rep, 13, pp.2258~2272 (2015)
  82. Polykratis, A., "A20 prevents inflammasome-dependent arthritis by inhibiting macrophage necroptosis through its ZnF7 ubiquitin-binding domain", Nat. Cell Biol, 21, pp.731~742 (2019)
  83. Bignell, G. R., "Identification of the familial cylindromatosis tumoursuppressor gene", Nat. Genet, 25, pp.160~165 (2000)
  84. Poblete, G. P., "Phenotype diversity in familial cylindromatosis: a frameshift mutation in the tumor suppressor gene CYLD underlies different tumors of skin appendages", J. Invest. Dermatol, 119, pp.527~531 (2002)
  85. Trompouki, E., "CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members", Nature, 424, pp.739~796 (2003)
  86. Sun, S. C., "Deubiquitylation and regulation of the immune response", Nat. Rev. Immunol, 8, pp.501~511 (2008)
  87. Brummelkamp, T. R., "Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB", Nature, 424, pp.797~801 (2003)
  88. Kovalenko, A., "The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination", Nature, 424, pp.801~805 (2003)
  89. Moquin, D. M., "CYLD deubiquitinates RIP1 in the TNFα-induced necrosome to facilitate kinase activation and programmed necrosis", PLoS One, 8, pp.e76841~ (2013)
  90. Legarda, D., "CYLD proteolysis protects macrophages from TNF-mediated auto-necroptosis induced by LPS and licensed by type I IFN", Cell Rep, 15, pp.2449~2461 (2016)
  91. Ganjam, G. K., "Cylindromatosis mediates neuronal cell death in vitro and in vivo", Cell Death Differ, 25, pp.1394~1407 (2018)
  92. Wright, A., "Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD", Dev. Cell, 13, pp.705~716 (2007)
  93. Alameda, J. P., "CYLD regulates keratinocyte differentiation and skin cancer progression in humans", Cell Death Dis, 2, pp.e208~ (2011)
  94. Hellerbrand, C., "Reduced expression of CYLD in human colon and hepatocellular carcinomas", Carcinogenesis, 28, pp.21~27 (2007)
  95. Wang, L., "CYLD deficiency enhances metabolic reprogramming and tumor progression in nasopharyngeal carcinoma via PFKFB3", Cancer Lett, 532, pp.215586~ (2022)
  96. Massoumi, R., "Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma", J. Exp. Med, 206, pp.221~232 (2009)
  97. Shinriki, S., "Loss of CYLD promotes cell invasion via ALK5 stabilization in oral squamous cell carcinoma", J. Pathol, 244, pp.367~379 (2018)
  98. Enesa, K., "NF-kappaB suppression by the deubiquitinating enzyme Cezanne : a novel negative feedback loop in pro-inflammatory signaling", J. Biol. Chem, 283, pp.7036~7045 (2008)
  99. Luong, L. A., "Cezanne regulates inflammatory responses to hypoxia in endothelial cells by targeting TRAF6 for deubiquitination", Circ. Res, 112, pp.1583~1591 (2013)
  100. Enesa, K., "Hydrogen peroxide prolongs nuclear localization of NF-kappaB in activated cells by suppressing negative regulatory mechanisms", J. Biol. Chem, 283, pp.18582~18590 (2008)
  101. Geserick, P., "Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment", J. Cell Biol, 187, pp.1037~1054 (2009)
  102. Hitomi, J., "Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway", Cell, 135, pp.1311~1323 (2008)
  103. Wang, L., "TNF-α induces two distinct caspase-8 activation pathways", Cell, 133, pp.693~703 (2008)
  104. Feoktistova, M., "cIAPs block ripoptosome formation, a RIP1", caspase-8containing intracellular cell death complex differentially regulated by cFLIP isoforms, 2011, pp.43, 449~463
  105. Tenev, T., "The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs", Mol. Cell, 43, pp.432~448 (2011)
  106. Bertrand, M. J., "The Ripoptosome: death decision in the cytosol", Mol. Cell, 43, pp.323~325 (2011)
  107. Meng, H., "Death-domain dimerization-mediated activation of RIPK1 controls necroptosis and RIPK1-dependent apoptosis", Proc. Natl Acad. Sci. USA, 115, pp.E2001~E2009 (2018)
  108. Laurien, L., "Autophosphorylation at serine 166 regulates RIP kinase 1-mediated cell death and inflammation", Nat. Commun, 11, pp.1747~ (2020)
  109. Wegner, K. W., "Complex pathologic roles of RIPK1 and RIPK3 : moving beyond necroptosis", Trends Pharmacol. Sci, 38, pp.202~225 (2017)
  110. Degterev, A., "Identification of RIP1 kinase as a specific cellular target of necrostatins", Nat. Chem. Biol, 4, pp.313~321 (2008)
  111. McQuade, T., "Positive and negative phosphorylation regulates RIP1-and RIP3-induced programmed necrosis", Biochem. J, 456, pp.409~415 (2013)
  112. Goossens, V., "Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity", Proc. Natl Acad. Sci. USA, 92, pp.8115~8119 (1995)
  113. Roca, F. J., "TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species", Cell, 153, pp.521~534 (2013)
  114. Sun, W., "Inhibition of lung cancer by 2-Methoxy-6-Acetyl-7-Methyljuglone through induction of necroptosis by targeting receptor-interacting protein 1", Antioxid. Redox Signal, 31, pp.93~108 (2019)
  115. Schenk, B., "Reactive oxygen species regulate Smac mimetic", TNFα-induced necroptotic signaling and cell death, 2015, pp.34, 5796~5806
  116. Zhang, Y., "RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruitment into necrosome", Nat. Commun, 8, pp.14329~ (2017)
  117. Delanghe, T., "RIPK1 kinase-dependent death:a symphony of phosphorylation events", Trends Cell Biol, 30, pp.189~200 (2020)
  118. Hacker, H., "Regulation and function of IKK and IKK-related kinases", Sci. STKE, pp.re13~ (2006)
  119. Dondelinger, Y., "Regulation of RIPK1’s cell death function by phosphorylation", Cell Cycle, 15, pp.5~6 (2016)
  120. Dondelinger, Y., "NF-κB-independent role of IKKα", IKKβ in preventing RIPK1kinase-dependent apoptotic and necroptotic cell death during TNF signaling, 2015, pp.60, 63~76
  121. Piao, X., "8-Geranylumbelliferone isolated from Paramignya trimera triggers RIPK1", RIPK3-dependent programmed cell death upon TNFR1 ligation, 2021, pp.192, 114733~
  122. Dondelinger, Y., "Serine 25 phosphorylation inhibits RIPK1 kinasedependent cell death in models of infection and inflammation", Nat. Commun, 10, pp.1729~ (2019)
  123. Lafont, E., "TBK1 and IKKepsilon prevent TNF-induced cell death by RIPK1phosphorylation", Nat. Cell Biol, 20, pp.1389~1399 (2018)
  124. Xu, D., "TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging", Cell, 1477–1491, pp.1419~ (2018)
  125. Chau, T. L., "Are the IKKs and IKK-related kinases TBK1 and IKK-epsilon similarly activated?", Trends Biochem. Sci, 33, pp.171~180 (2008)
  126. Dondelinger, Y., "RIPK3 contributes to TNFR1-mediated RIPK1 kinasedependent apoptosis in conditions of cIAP1", 2 depletion or TAK1 kinase inhibition, 2013, pp.20, 1381~1392
  127. Totzke, J., "Takinib, a selective TAK1 inhibitor, broadens the therapeutic efficacy of TNF-α inhibition for cancer and autoimmune disease", Cell Chem. Biol, 24, pp.1029~1039 (2017)
  128. Kang, K., "3-O-acetylrubianol C(3AR-C)induces RIPK1-dependent programmed cell death by selective inhibition of IKKβ", FASEB J, 34, pp.4369~4383 (2020)
  129. Geng, J., "Regulation of RIPK1 activation by TAK1-mediated phosphorylation dictates apoptosis and necroptosis", Nat. Commun, 8, pp.359~ (2017)
  130. Janes, K. A., "Cytokine-induced signaling networks prioritize dynamic range over signal strength", Cell, 135, pp.343~354 (2008)
  131. Gaestel, M., "Targeting innate immunity protein kinase signalling in inflammation", Nat. Rev. Drug Discov, 8, pp.480~499 (2009)
  132. Lalaoui, N., "Targeting p38 or MK2 enhances the anti-leukemic activity of Smac-mimetics", Cancer Cell, 30, pp.499~500 (2016)
  133. Vandendriessche, B., "MAPK-activated protein kinase 2-deficiency causes hyperacute tumor necrosis factor-induced inflammatory shock", BMC Physiol, 14, pp.5~ (2014)
  134. Jaco, I., "MK2 phosphorylates RIPK1 to prevent TNF-i nduced cell death", Mol. Cell, 66, pp.698~710.e695 (2017)
  135. Menon, M. B., "p38(MAPK)", MK2-dependent phosphorylation controls cytotoxic RIPK1 signalling in inflammation and infection, 2017, pp.19, 1248~1259
  136. Oberst, A., "MK2 balances inflammation and cell death", Nat. Cell Biol, 19, pp.1150~1152 (2017)
  137. Dondelinger, Y., "MK2 puts an additional brake on RIPK1 cytotoxic potential", Cell Death Differ, 25, pp.457~459 (2018)
  138. Micheau, O., "Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes", Cell, 114, pp.181~190 (2003)
  139. de Almagro, M. C., "Coordinated ubiquitination and phosphorylation of RIP1regulates necroptotic cell death", Cell Death Differ, 24, pp.26~37 (2017)
  140. Wang, H., "PELI1 functions as a dual modulator of necroptosis and apoptosis by regulating ubiquitination of RIPK1 and mRNA levels of c-FLIP", Proc. Natl Acad. Sci. USA, 114, pp.11944~11949 (2017)
  141. Moynagh, P. N., "The roles of Pellino E3 ubiquitin ligases in immunity", Nat. Rev. Immunol, 14, pp.122~131 (2014)
  142. Weinlich, R., "The two faces of receptor interacting protein kinase-1", Mol. Cell, 56, pp.469~480 (2014)
  143. Seo, J., "CHIP controls necroptosis through ubiquitylation-and lysosomedependent degradation of RIPK3", Nat. Cell Biol, 18, pp.291~302 (2016)
  144. Choi, S. W., "PELI1 selectively targets kinase-active RIP3 for ubiquitylation dependent proteasomal degradation", Mol. Cell, 70, pp.920~935 (2018)
  145. He, S., "RIP kinases as modulators of inflammation and immunity", Nat. Immunol, 19, pp.912~922 (2018)
  146. Nakano, H., "Regulation of the release of damage-associated molecular patterns from necroptotic cells", Biochem. J, 479, pp.677~685 (2022)
  147. Liu, Z., "Regulatory mechanisms of RIPK1 in cell death and inflammation", Semin. Cell Dev. Biol, 109, pp.70~75 (2021)
  148. Witt, A., "Diverse ubiquitin linkages regulate RIP kinases-mediated inflammatory and cell death signaling", Cell Death Differ, 24, pp.1160~1171 (2017)
  149. Newton, K., "RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury", Cell Death Differ, 23, pp.1565~1576 (2016)
  150. Harris, P. A., "Discovery of a first-in-class receptor interacting protein 1(RIP1)kinase specific clinical candidate(GSK2982772)for the treatment of inflammatory diseases", J. Med. Chem, 60, pp.1247~1261 (2017)
  151. Weisel, K., "A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis", Arthritis Res. Ther, 23, pp.85~ (2021)
  152. Mifflin, L., "Receptor-interacting protein kinase 1(RIPK1)as a therapeutic target", Nat. Rev. Drug Discov, 19, pp.553~571 (2020)
  153. Li, S., "Novel insights into RIPK1 as a promising target for future Alzheimer’s disease treatment", Pharmacol. Ther, 231, pp.107979~ (2022)
  154. Mantovani, A., "Cancer-related inflammation", Nature, 454, pp.436~444 (2008)
  155. Balkwill, F., "Inflammation and cancer: back to Virchow?", Lancet, 357, pp.539~545 (2001)
  156. Palucka, A. K., "The basis of oncoimmunology", Cell, 164, pp.1233~1247 (2016)
  157. Wang, W., "RIP1 kinase drives macrophage mediated adaptive immune tolerance in pancreatic cancer", Cancer Cell, 34, pp.757~774 (2018)
  158. Li, Y., "Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases", Proc. Natl Acad. Sci. USA, 116, pp.970~975 (2019)
  159. Cuchet-Lourenço, D., "RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation", Science, 361, pp.810~813 (2018)
  160. Yatim, N., "Dying cells actively regulate adaptive immune responses", Nat. Rev. Immunol, 17, pp.262~275 (2017)
  161. Yatim, N., "RIPK1 and NF-kappaB signaling in dying cells determines crosspriming of CD8(+)T cells", Science, 350, pp.328~334 (2015)
  162. Aaes, T. L., "Vaccination with necroptotic cancer cells induces efficient antitumor immunity", Cell Rep, 15, pp.274~287 (2016)
  163. Snyder, A. G., "Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity", Sci. Immunol, 4, pp.eaaw2004~ (2019)
  164. Sharma, S. K., "Development of peptidomimetics targeting IAPs", Int. J. Pept. Res. Ther, 12, pp.21~32 (2006)
  165. Kipp, R. A., "Molecular targeting of inhibitor of apoptosis proteins based on small molecule mimics of natural binding partners", Biochemistry, 41, pp.7344~7349 (2002)
  166. Derrick, J. C., "Smac mimetics as new cancer therapeutics", Anti-Cancer Drugs, 20, pp.646~658 (2009)
  167. Rathore, R., "Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)", Apoptosis, 22, pp.898~919 (2017)
  168. Fulda, S., "Targeting IAP proteins for therapeutic intervention in cancer", Nat. Rev. Drug Discov, 11, pp.109~124 (2012)
  169. Cetraro, P., "A review of the current impact of inhibitors of apoptosis proteins and their repression in cancer", Cancers(Basel), 14, pp.1671~ (2022)
  170. Lecis, D., "Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity", Cell Death Dis, 4, pp.e920~ (2013)
  171. Tanzer, M. C., "Combination of IAP antagonist and IFNgamma activates novel caspase-10-and RIPK1-dependent cell death pathways", Cell Death Differ, 24, pp.481~491 (2017)
  172. Rettinger, E., "SMAC mimetic BV6 enables sensitization of resistant tumor cells but also affects Cytokine-Induced Killer(CIK)cells : a potential challenge for combination therapy", Front Pediatr, 2, pp.75~ (2014)
  173. Bake, V. R., "Interaction of Smac mimetic and IFNalpha to trigger apoptosis in acute myeloid leukemia cells", Cancer Lett, 355, pp.224~231 (2014)
  174. Condon, S. M., "Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies", J. Med. Chem, 57, pp.3666~3677 (2014)
  175. Cong, H., "Inhibitor of apoptosis protein (IAP) antagonists in anticancer agent discovery: current status and perspectives", J. Med. Chem, 62, pp.5750~5772 (2019)
  176. Infante, J. R., "Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors", J. Clin. Oncol, 32, pp.3103~3110 (2014)
  177. Noonan, A. M., "Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or-refractory epithelial ovarian cancer", Cancer, 122, pp.588~597 (2016)
  178. Brumatti, G., "The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia", Sci. Transl. Med, 8, pp.339~369 (2016)
  179. Martínez-Limón, A., "The p38pathway : from biology to cancer therapy", Int. J. Mol. Sci, 21, pp.1913~ (2020)
  180. Lou, J., "Caspase-independent regulated necrosis pathways as potential targets in cancer management", Front. Oncol, 10, pp.616952~ (2021)
  181. Krysko, O., "Necroptotic cell death in anti-cancer therapy", Immunol. Rev, 280, pp.207~219 (2017)
  182. Kang, T. B., "Caspase-8deficiency in mouse embryos triggers chronic RIPK1-dependent activation of inflammatory genes, independently of RIPK3", Cell Death Differ, 25, pp.1107~1117 (2018)

관련 논문AI추천

Roles of RIPK3 in necroptosis, cell signaling, and diseaseKim You-Sun, Morgan Michael J.생화학분자생물학회 · Experimental and Molecular Medicine2022 · 제54권 The serine threonine kinase RIP3: lost and found김유선, Michael J. Morgan생화학분자생물학회 · BMB Reports2015 · 제48권 제6호Receptor Interacting Protein 3 Kinase Regulates Caspase-independent Programmed Necrosis조영식자연과학연구소 · Quantitative Bio-Science2013 · 제32권 제1호The role of necroptosis in the treatment of diseases조영식생화학분자생물학회 · BMB Reports2018 · 제51권 제5호Regulation of RIP3 protein stability by PELI1-mediated proteasome-dependent degradation강호철, 김유선, 박한희, Michael J. Morgan생화학분자생물학회 · BMB Reports2018 · 제51권 제10호New role of E3 ubiquitin ligase in the regulation of necroptosis서진호, 송재환, 이은우생화학분자생물학회 · BMB Reports2016 · 제49권 제5호

이 간행물의 다른 논문 (191건)

Particulate matter promotes cancer metastasis through increased HBEGF expression in macrophages이효진, Park Jun-Young, Lee Moo-Seung, Kim Dae-Soo, Son Mi-Young, Jeong Jinyoung, 박영준, Cho Young-Lai, Lee Seon-Jin, Park Seung-Ho, Yoon Sung-Jin, Choi Song, Jung Jaeeun, Park Young-Ho, Seo Jinho, Lee Jungwoon, Kim Jang-Seongpp. 1-12WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function권호근, 김현석, Yoon Hyun Ju, Kim Gi-Cheon, Oh Sejin, Kim Hakhyun, Kim Yong Keon, Lee Yunji, Kim Min Seo, Kwon Gino, Ok Yeon-Supp. 1-14Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagyFeng Ji, Wu Yong, Zhou Jing, Dai Hui-Qi, Zhu Guang-Zhi, Chen Pan-Hong, Wang Li-Ming, Lu Guang, Liao Xi-Wen, Lu Pei-Zhi, Su Wen-Jing, Hooi Shing Chuan, Ye Xin-Pin, Shen Han-Ming, Peng Tao, Lu Guo-Dongpp. 1-15Hypoxia-induced circRNF13 promotes the progression and glycolysis of pancreatic cancerZhao Qiuyan, Zhu Zhonglin, Xiao Wenqin, Zong Guanzhao, Wang Chuanyang, Jiang Weiliang, Li Kai, Shen Jie, Guo Xingya, Cui Jianhua, Guo Lihong, Wan Rongpp. 1-15The transcriptional profile of keloidal Schwann cellsDireder Martin, Wielscher Matthias, Weiss Tamara, Laggner Maria, Copic Dragan, Klas Katharina, Bormann Daniel, Vorstandlechner Vera, Tschachler Erwin, Jan Ankersmit Hendrik, Mildner Michaelpp. 1-15
원문 보기